US Vaccine Committee Axes Universal Hepatitis B Shot for Newborns, Shifts to Individualized Approach.
The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) voted 8-3 to scrap the universal recommendation for the hepatitis B vaccine at birth. This move marks a significant shift towards an individualized approach, with parents being advised to consult their healthcare provider about vaccinating their newborn if they test negative for the virus.
According to the new guidelines, infants born to mothers who test positive or have unknown hepatitis B status will still receive the vaccination. However, children born to mothers who test negative will need to weigh the risks against the benefits of vaccination and make an informed decision with the guidance of their healthcare provider.
The vote also included a provision for newborns who do not receive the hepatitis B birth dose before the age of 2 months to receive an initial dose at that time. The ACIP emphasized there has been no change in recommending vaccinations for infants born to women who test positive or have unknown status.
Experts suggest considering whether the newborn is exposed to individuals with hepatitis B, such as household members or frequent contacts from countries where hepatitis B is prevalent. A footnote accompanying the document advised parents and healthcare providers to weigh these risks against vaccination benefits.
The changes will be reviewed by the CDC's acting director, Jim O'Neill, who is expected to sign off on the revised guidelines.
The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) voted 8-3 to scrap the universal recommendation for the hepatitis B vaccine at birth. This move marks a significant shift towards an individualized approach, with parents being advised to consult their healthcare provider about vaccinating their newborn if they test negative for the virus.
According to the new guidelines, infants born to mothers who test positive or have unknown hepatitis B status will still receive the vaccination. However, children born to mothers who test negative will need to weigh the risks against the benefits of vaccination and make an informed decision with the guidance of their healthcare provider.
The vote also included a provision for newborns who do not receive the hepatitis B birth dose before the age of 2 months to receive an initial dose at that time. The ACIP emphasized there has been no change in recommending vaccinations for infants born to women who test positive or have unknown status.
Experts suggest considering whether the newborn is exposed to individuals with hepatitis B, such as household members or frequent contacts from countries where hepatitis B is prevalent. A footnote accompanying the document advised parents and healthcare providers to weigh these risks against vaccination benefits.
The changes will be reviewed by the CDC's acting director, Jim O'Neill, who is expected to sign off on the revised guidelines.